However, exogenous TRPV1 agonists, although reducing tumor cell viability at high concentrations in vitro [13,17], fail to induce the overstimulation-based cytotoxicity observed in pain-sensing neurons, even at lower concentrations [13]. The gene discussed is TRPV1; the disease is neoplasm.